Skip to main content
. 2020 Nov 11;10(11):e040092. doi: 10.1136/bmjopen-2020-040092

Table 4.

Prevalence ratio (PR) of general attitudes towards HIV cure research between groups based on gender, employment status, education and the belief that an HIV cure is available

Gender (TGW/ W vs travestis) Employment status (employed vs unemployed) Education (at least high school vs until incomplete high school) Believe that HIV cure is available (Yes vs No)
PR 95% CI P value PR 95% CI P value PR 95% CI P value PR 95% CI P value
More education about cure research is needed before a cure is accepted by community 1.01 0.86 to 1.18 0.88 0.83 0.66 to 1.03 0.03 1.15 0.97 to 1.37 0.07 1.08 0.93 to 1.26 0.35
People living with HIV are discriminated against 1.03 0.87 to 1.24 0.74 0.97 0.79 to 1.19 0.78 1.21 0.98 to 1.49 0.04 1.15 0.99 to 1.35 0.11
A cure would prevent people from using HIV prevention methods 0.79 0.58 to 1.08 0.16 0.69 0.45 to 1.04 0.05 0.88 0.64 to 1.22 0.45 0.76 0.51 to 1.15 0.16
High costs of HIV cure would prevent people from taking it 0.97 0.73 to 1.29 0.86 0.80 0.58 to 1.12 0.17 1.31 0.97 to 1.76 0.07 1.04 0.78 to 1.37 0.81
I can trust my healthcare provider’s decisions on medical treatments 1.03 0.82 to 1.29 0.80 0.79 0.60 to 1.05 0.07 1.11 0.89 to 1.39 0.35 0.91 0.71 to 1.17 0.44
A cure that would stop the need for all treatment would be desirable 1.08 0.77 to 1.51 0.66 0.72 0.48 to 1.08 0.08 0.89 0.64 to 1.23 0.48 1.05 0.75 to 1.46 0.78
I completely trust my healthcare provider 0.95 0.75 to 1.19 0.66 0.82 0.62 to 1.08 0.12 1.04 0.82 to 1.31 0.77 0.90 0.69 to 1.16 0.41
The dangers of a new cure may be too high 1.22 0.86 to 1.73 0.24 1.11 0.80 to 1.54 0.54 1.16 0.81 to 1.66 0.39 0.96 0.67 to 1.37 0.81
There will never be a cure for HIV 0.68 0.37 to 1.24 0.21 1.00 0.52 to 1.92 1.00 0.76 0.41 to 1.42 0.39 0.56 0.25 to 1.23 0.12
We do not need a cure 0.64 0.29 to 1.42 0.27 0.78 0.31 to 1.96 0.59 0.94 0.42 to 2.11 0.88 0.79 0.32 to 1.95 0.59

Bolded values represent statistically significant findings (p < 0.05).